Bristol-Myers Squibb Co GF Score

: 87/100 (As of Today)

View and export this data going back to 1952. Start your Free Trial

Bristol-Myers Squibb Co has the GF Score of 87, which implies that the company might have Good outperformance potential.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 5/10
2. Profitability Rank : 8/10
3. Growth Rank : 9/10
4. GF Value Rank : 5/10
5. Momentum Rank : 6/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Bristol-Myers Squibb Co might have Good outperformance potential.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Bristol-Myers Squibb Co GF Score Distribution

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's GF Score distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's GF Score falls into.

Bristol-Myers Squibb Co (NYSE:BMY) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Bristol-Myers Squibb Co GF Score Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Bristol-Myers Squibb Co Business Description

Industry

Healthcare » Drug Manufacturers NAICS : 325412 SIC : 2834

Comparable Companies

NAS:AMGN NYSE:MRK NAS:GILD NYSE:ABBV NYSE:PFE NAS:BIIB NYSE:LLY NAS:HZNP NYSE:OGN NAS:CRXT NYSE:JNJ XSWX:ROG LSE:AZN XSWX:NOVN XPAR:SAN LSE:GSK XTER:BAYN TSE:4519 TSE:4568 SHSE:600276

Traded in Other Exchanges

BMY.R:USA BMYMP.PFD:USA BMY:Mexico 0R1F:UK BRM:Germany BRM:Germany BRM:Germany BRM:Germany BMYB34:Brazil BMYS:Austria BMY:Argentina

Address

430 East 29th Street, 14th Floor, New York, NY, USA, 10016

Website

https://www.bms.com

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Executives

Vousden Karen H	director	345 PARK AVENUE NEW YORK NY 10154
Samuels Theodore R. Ii	director	1990 E. GRAND AVE. EL SEGUNDO CA 90245
Haller Julia A	director	C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901
Paliwal Dinesh C	director	5454 W 110TH STREET OVERLAND PARK KS 66211
Rice Derica W	director	LILLY CORPORATE CENTER INDIANAPOLIS IN 46285
Emmens Matthew	director	C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST., ATTN: GENERAL COUNSEL CAMBRIDGE MA 02139
Bertolini Robert J	director	C/O SCHERING PLOUGH CORP 2000 GALLOPING HILL RD KENILWORTH NJ 070333
Price Paula A	director	ONE CVS DRIVE WOONSOCKET RI 02895
Yale Phyllis R	director	PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: YALE PHYLLIS R a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Bonney Michael W	director	65 HAYDEN AVE LEXINGTON MA 02421
Arduini Peter J	director	311 ENTERPRISE DRIVE PLAINSBORO NJ 08536
Santiago Karen Murphy	officer: SVP & Controller	BRISTOL-MYERS SQUIBB COMPANY RT. 206 & PROVINCE LINE ROAD PRINCETON NJ 08540
Caforio Giovanni	director, officer: Chairman and CEO	BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 & PROVINCELINE ROAD LAWRENCEVILLE NJ 08543
Eid Joseph	officer: SVP,Head Glob. Medical Affairs	BRISTOL-MYERS SQUIBB COMPANY 3401 PRINCETON PIKE LAWRENCEVILLE NJ 08648
Leung Sandra	officer: EVP, General Counsel	C/O BRISTOL MYERS SQUIBB CO 345 PARK AVE NEW YORK NY 10164